Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Envoy Medical (COCH) Long-Term Deferred Tax (2022 - 2023)

Envoy Medical's Long-Term Deferred Tax history spans 2 years, with the latest figure at $50.2 million for Q4 2023.

On a quarterly basis, Long-Term Deferred Tax rose 13.08% to $50.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $50.2 million, a 13.08% increase, with the full-year FY2023 number at $50.2 million, up 13.08% from a year prior.
Long-Term Deferred Tax hit $50.2 million in Q4 2023 for Envoy Medical, up from $44.4 million in the prior quarter.
Over the last five years, Long-Term Deferred Tax for COCH hit a ceiling of $50.2 million in Q4 2023 and a floor of $44.4 million in Q4 2022.